{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T18:38:03Z","timestamp":1784140683509,"version":"3.55.0"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Orelabrutinib is a second-generation Bruton tyrosine kinase inhibitor that improves the management of B-cell malignancies. The objective of this study was to develop and validate an LC-MS\/MS method for quantifying orelabrutinib in human plasma.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Plasma samples were processed using acetonitrile to precipitate proteins. Ibrutinib-d5 was used as the internal standard. The mobile phase comprised 10 mM ammonium formate containing 0.1% formic acid and acetonitrile (62:38, vol\/vol). The multiple reaction monitoring transitions at <jats:italic toggle=\"yes\">m<\/jats:italic>\/<jats:italic toggle=\"yes\">z =<\/jats:italic> 428.1 \u2192 411.2 and 446.2 \u2192 309.2 were selected for orelabrutinib and ibrutinib-d5, respectively, after ionization in the positive mode.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Total runtime was 4.5 minutes. The validated curve ranges were 1.00\u2013500 ng\/mL. This method exhibited acceptable selectivity, dilution integrity, matrix effects, and recovery. Interrun and intrarun accuracy ranged from \u22123.4% to 6.5%, and interrun and intrarun precision was between 2.8% and 12.8%. Stability was studied under different conditions. The incurred sample reanalysis demonstrated good reproducibility.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The LC-MS\/MS method provided a simple, specific, and rapid quantification of orelabrutinib in the plasma of patients with mantle cell lymphoma or chronic lymphocytic leukemia\/small lymphocytic lymphoma. The results indicated that orelabrutinib exhibits large variability between individuals and should be prudently used in combination with CYP3A4 inhibitors.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001106","type":"journal-article","created":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:05:32Z","timestamp":1684411532000},"page":"599-605","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Determination of Orelabrutinib in Human Plasma Using LC-MS\/MS"],"prefix":"10.1097","volume":"45","author":[{"given":"Yang","family":"Zhao","sequence":"first","affiliation":[{"name":"Research Division of Clinical Pharmacology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China; and"},{"name":"School of Pharmacy, Nanjing Medical University, Nanjing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Jiao","family":"Guo","sequence":"additional","affiliation":[{"name":"Research Division of Clinical Pharmacology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-Long","family":"Chen","sequence":"additional","affiliation":[{"name":"Research Division of Clinical Pharmacology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Ling","family":"Yang","sequence":"additional","affiliation":[{"name":"Research Division of Clinical Pharmacology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China; and"},{"name":"School of Pharmacy, Nanjing Medical University, Nanjing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Ma","sequence":"additional","affiliation":[{"name":"Research Division of Clinical Pharmacology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Qing","family":"Wang","sequence":"additional","affiliation":[{"name":"Research Division of Clinical Pharmacology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China; and"},{"name":"School of Pharmacy, Nanjing Medical University, Nanjing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu-Ning","family":"Sun","sequence":"additional","affiliation":[{"name":"Research Division of Clinical Pharmacology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China; and"},{"name":"School of Pharmacy, Nanjing Medical University, Nanjing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,5,5]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s12272-019-01124-1","article-title":"Development of BTK inhibitors for the treatment of B-cell malignancies","volume":"42","author":"Kim","year":"2019","journal-title":"Arch Pharm Res."},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11523-021-00857-8","article-title":"Bruton tyrosine kinase inhibitors in B-cell malignancies: their use and differential features","volume":"17","author":"Shirley","year":"2022","journal-title":"Target Oncol."},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.omto.2021.03.015","article-title":"Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma","volume":"21","author":"Yu","year":"2021","journal-title":"Mol Ther Oncolytics"},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.hoc.2020.06.007","article-title":"Current role and emerging evidence for Bruton tyrosine kinase inhibitors in the treatment of mantle cell lymphoma","volume":"34","author":"Bond","year":"2020","journal-title":"Hematol Oncol Clin North Am."},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3390\/cancers14030771","article-title":"The role of Bruton's kinase inhibitors in chronic lymphocytic leukemia: current status and future directions","volume":"14","author":"Robak","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1007\/s10637-022-01219-5","article-title":"Orelabrutinib-Bruton tyrosine kinase inhibitor-based regimens in the treatment of central nervous system lymphoma: a retrospective study","volume":"40","author":"Wu","year":"2022","journal-title":"Invest New Drugs"},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"901797","DOI":"10.3389\/fonc.2022.901797","article-title":"Orelabrutinib combined with lenalidomide and immunochemotherapy for relapsed\/refractory primary central nervous system lymphoma: a retrospective analysis of case series","volume":"12","author":"Yang","year":"2022","journal-title":"Front Oncol."},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s40265-021-01482-5","article-title":"Orelabrutinib: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"issue":"suppl 1","key":"R9-20250603","doi-asserted-by":"crossref","first-page":"i5","DOI":"10.1093\/jac\/dkq437","article-title":"Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients","volume":"66","author":"Pagano","year":"2011","journal-title":"J Antimicrob Chemother."},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.cmi.2015.02.019","article-title":"Epidemiology of invasive fungal diseases among patients with haematological disorders in the Asia-Pacific: a prospective observational study","volume":"21","author":"Hsu","year":"2015","journal-title":"Clin Microbiol Infect."},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1016\/S2352-3026(21)00232-5","article-title":"Management of drug-drug interactions of targeted therapies for haematological malignancies and triazole antifungal drugs","volume":"9","author":"Br\u00fcggemann","year":"2022","journal-title":"Lancet Haematol."},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1080\/00498254.2021.1969481","article-title":"Impact of CYP2C19 genotype on voriconazole exposure and effect of voriconazole on the activity of CYP3A in patients with haematological malignancies","volume":"51","author":"Huang","year":"2021","journal-title":"Xenobiotica"},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1080\/14656566.2022.2144218","article-title":"Evaluating orelabrutinib as a novel treatment option for relapsed\/refractory chronic lymphocytic leukemia in China","volume":"23","author":"Gu","year":"2022","journal-title":"Expert Opin Pharmacother."},{"issue":"suppl 1","key":"R14-20250603","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1182\/blood-2021-146491","article-title":"Orelabrutinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma: updated long term results of phase II study","volume":"138","author":"Xu","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"R15-20250603","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood-2020-140172","article-title":"Pooled analysis of safety data from clinical trials of orelabrutinib monotherapy in hematologic malignancies","volume":"136","author":"Song","year":"2020","journal-title":"Blood"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001106","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:11:56Z","timestamp":1748970716000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,5]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001106","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5,5]]},"assertion":[{"value":"2022-10-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}